DeMartino JK. Measuring quality in oncology: challenges and opportunities. J Natl Compr Cancer Netw. 2013;11(12):1482–91.
Institute of Medicine. Crossing the quality chasm: a new health system for the 21th century. IOM. 2001.
Donabedian A. Evaluating the quality of medical care. Milbank Mem Fund Q. 1966;44(3):166–206.
Donabedian A. The quality of care: how can it be assessed? JAMA. 1988;260(12):1743–8.
Adess L, Itzykson R, Fenaux P. Myelodysplastic syndromes. Lancet. 2014;383:2239–52.
Tefferi A, Vardiman JW. Myelodysplastic syndromes. NEJM. 2009;361:1872–85.
Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the WHO classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937–52.
Abel GA, Van Bennekom CM, Stone RM, Anderson TE, Kaufman DW. Classification of the myelodysplastic syndrome in a national registry of recently diagnosed patients. Leuk Res. 2010;34(7):939–41.
Balleari E, Salvetti C, Del Corso L, Filiberti R, Bacigalupo A, Bellodi A, et al. Age and comorbidities deeply impact on clinical outcome of patients with myelodysplastic syndromes. Leuk Res. 2015;39(8):846–52.
Neukirchen J, Nachtkamp K, Schemenau J, Aul C, Giagounidis A, Strupp C, et al. Change of prognosis of patients with myelodysplastic syndromes during the last 30 years. Leuk Res. 2015;39(7):679–83.
National Quality Forum. Cancer measures endorsement summary. 2012.
Greenberg PL, Sun Z, Miller KB, Bennett JM, Tallman MS, Dewald G, et al. Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor : results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). Blood. 2009;114(12):2393–400.
Greenberg PL, Cosler LE, Ferro SA, Lyman GH. The costs of drugs used to treat myelodysplastic syndromes following national comprehensive cancer network guidelines. J Natl Compr Cancer Netw. 2008;6(9):942–53.
Nissenson AR. Hyporesponsiveness to erythropoietin: overview, 1996. Perit Dial Int. 1996;16(13):417–20.
Abel GA, Cronin AM, Odejide OO, Uno H, Stone RM, Steensma DP. Influence of Patient and Provider Characteristics on Quality of Care for the Myelodysplastic Syndromes. BJH. 2016;in press. The authors found suboptimal rates of adherence to two accepted MDS quality standards: marrow cytogenetic testing (found to be 74% of patients) and pre-erythropoietin therapy iron assessment (found to be 56% of patients).
Davidoff AJ, Weiss SR, Baer MR, Ke X, Hendrick F, Zeidan A, et al. Patterns of erythropoiesis-stimulating agent use among Medicare beneficiaries with myelodysplastic syndromes and consistency with clinical guidelines. Leuk Res. 2013;37(6):675–80. The authors found low rates of adherence to NCCN guidelines for erythropoietin therapy in MDS such as (1) it should be administered to low-risk patients for a minimum of 8 weeks and (2) serum erythropoietin levels should be measured prior to initiating therapy.
CMS. Computation of the 2016 Value Modifier Fact Sheet. Centers Medicare Medicaid Serv. 2015.
CMS. Detailed Methodology for the 2016 Value Modifier and the 2014 Quality and Resource Use Report. Centers Medicare Medicaid Serv. 2015.
NCCN. Myelodysplastic syndromes. NCCN Clin Pract Guidel Oncol. 2016;Version 1.
Sekeres MA, Stowell SA, Berry CA, Mencia WM, Dancy JN. Improving the diagnosis and treatment of patients with myelodysplastic syndromes through a performance improvement initiative. Leuk Res. 2013;37(4):422–6.
Burwell SM. Setting value-based payment goals—HHS efforts to improve U.S. health care. N Engl J Med. 2015;372(10):897–9.
Odejide OO, Cronin AM, Earle CC, Lacasce AS, Abel GA. Hospice use among patients with lymphoma: impact of disease aggressiveness and curability. J Natl Cancer Inst. 2016;108(1):1–8.
Earle CC, Landrum MB, Souza JM, Neville BA, Weeks JC, Ayanian JZ. Aggressiveness of cancer care near the end of life: is it a quality-of-care issue? J Clin Oncol. 2008;26(23):3860–6.
Hui D, Didwaniya N, Vidal M, Shin SH, Chisholm G, Roquemore J, et al. Quality of end-of-life care in patients with hematologic malignancies: a retrospective cohort study. Cancer. 2014;120(10):1572–8.
Fletcher SA, Cronin AM, Zeidan AM, Odejide OO, Gore SD, Davidoff AJ, et al. Intensity of end-of-life care for patients with myelodysplastic syndromes: findings from a Large National Database. Cancer. 2016; in press. The investigators assessed the quality of MDS end-of-life care via traditional quality measures: admission to the ICU in the last month of life (28%) and enrollment in hospice care (49%). They concluded that EOL care for patients with MDS was potentially suboptimal.
Wildiers H, Heeren P, Puts M, Topinkova E, Janssen-Heijnen MLG, Extermann M, et al. International society of geriatric oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol. 2014;32(24):2595–603.
NCCN. Older adult oncology. NCCN Clin Pract Guidel Oncol. 2016.
Buckstein R, Wells RA, Zhu N, Leitch HA, Nevill TJ, Yee KWL, et al. Patient-related factors independently impact overall survival in patients with myelodysplastic syndromes: an MDS-CAN prospective study. Br J Haematol. 2016;epub ahead:1–14.
Caocci G, Voso MT, Angelucci E, Stauder R, Cottone F, Abel G, et al. Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes. Leuk Res. 2015;39(8):859–65. The authors found that physicians’ beliefs about the decision-making style of their patients (active, collaborative or passive) was only concordant with patients’ self-reported style in half (49%) of cases. Physicians also overestimated their patients self-reported QOL. This is potentially suboptimal with respect to quality patient-centered care.
Efficace F, Gaidano G, Breccia M, Voso MT, Cottone F, Angelucci E, et al. Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study. Lancet Oncol. 2015;16:1506–14. The authors found that for patients with MDS, higher fatigue scores were independently associated with poorer overall survival, even when controlling for disease risk.
Gotay C. Fatigue and mortality: from description to action. Lancet Oncol. 2015;2045(15):15–6.
Smith AR, Warlick ED, Roesler MA, Poynter JN, Richardson M, Nguyen P, et al. Factors associated with hematopoietic cell transplantation (HCT) among patients in a population-based study of myelodysplastic syndrome (MDS) in Minnesota. Ann Hematol. 2015;94(10):1667–75. The authors reported factors associated with hematopoietic stem cell transplantation in MDS, finding that higher-income and more highly educated patients were more likely to undergo transplantation. This finding may represent inequitable and lower-quality care.
Pease DF, Ross JA, Poynter JN, Nguyen PL, Hirsch B, Cioc A, et al. Differences in community and academic practice patterns for newly diagnosed myelodysplastic syndromes (MDS) patients. Cancer Epidemiol. 2015;39(2):222–8.
Jha AK, Joynt KE, Orav EJ, Epstein AM. The long-term effect of premier pay for performance on patient outcomes. N Engl J Med. 2012;366(17):1607–15.
Petersen LA. Effects of individual physician-level and practice-level financial incentives on hypertension care. JAMA. 2013;310(10):1042–50.
Scott A, Sivey P, Ait Ouakrim D, Willenberg L, Naccarella L, Furler J, et al. The effect of financial incentives on the quality of health care provided by primary care physicians. Cochrane Database Syst Rev. 2011;7(9):CD008451.
Dolor RJ, Schulman KA. Financial incentives in primary care practice: the struggle to achieve population health goals. JAMA. 2013;310(10):1031–2.
Zon RT, Frame JN, Neuss MN, Page RD, Wollins DS, Stranne S, et al. American Society of Clinical Oncology Policy Statement on Clinical Pathways in Oncology. J Oncol Pract. 2016;epub ahead.
Jacobson J. Physicians as champions for quality improvement. ASCO Post. 2016.